Mirxes Holding Company Limited

2629

KYG6152E1052

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 06:02:13 06/03/2026 GMT			5-day change	1st Jan Change
15.09 ^HKD	-0.79%		-10.67%	-65.60%

03-05	Mirxes Holding wins bid for Lianxi gastric cancer screening, early intervention project	RE
03-05	Mirxes Wins Bid for Gastric Screening Project in China	MT

Mirxes to Raise HK$673 Million via Share Placement; Shares Fall 9%

Published on 01/29/2026 at 04:31 am GMT

MT Newswires

Latest news about Mirxes Holding Company Limited

03-05	Mirxes Holding wins bid for Lianxi gastric cancer screening, early intervention project	RE
03-05	Mirxes Wins Bid for Gastric Screening Project in China	MT
02-26	Mirxes Plans India Cancer Screening Tie-Up With Apollo Health and Lifestyle	MT
02-26	Mirxes Holding Company Limited Enters into A Memorandum of Understanding with Apollo Health and Lifestyle Limited	CI
02-23	Mirx Holding Company Limited Announces Completion of Enrolment in CADENCE CRC	CI
02-23	229,722,331 Ordinary Shares of Mirxes Holding Company Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
02-11	Mirxes Co-founders, Cornerstone Investors Undertake Voluntary Lock-up of Shares	MT
02-06	Mirxes Nets HK$673 Million via Share Placement	MT
01-29	Mirxes to Raise HK$673 Million via Share Placement; Shares Fall 9%	MT
01-29	Mirxes Holding announces placing 21.9 million shares at HK$32.50/share	RE
01-12	Mirxes Expands Thailand Business With Hospital Partnership, Home Test Launch	MT
01-09	Mirx Holding Company Limited Launches Its New Range of At-Home Screening Test Kits in Thailand	CI
01-09	Mirx Holding Company Limited Enters into A Strategic Partnership with N Health	CI
12-22	Mirxes Holding Company Limited(SEHK:2629) added to S&P Global BMI Index	CI
12-05	Mirxes Holding enters MoU with XtalPi Holdings	RE

Chart Mirxes Holding Company Limited

Duration

Period

2629: Dynamic Chart

MiRXES Holding Company Limited is a ribonucleic acid (RNA) technology company that is engaged in providing diagnostic solutions for the early detection of diseases accessible on a global scale. The Company is engaged developing and commercializing non-invasive blood-based microRNA (miRNA) test kits for the early detection of cancer and other diseases. The Company operates through two business segments: Early Detection and Precision Multi-omics segment, and Infectious Diseases segment. The Company offers various disease early detection products (including Core Product GASTROClear) and services, multi-omics candidate discovery and clinical genomic testing through its Early Detection and Precision Multi-omics segment. Its Early Detection product candidates includes LungClear, CRC-1, CADENCE and PHinder. Its Precision Multi-omics focuses on providing complex, miRNA centric multi-omics testing solutions to bio-pharmaceutical companies, and government organizations.

Employees

347

Sector

Biotechnology & Medical Research

More about the company